関連する実験動画
Updated: Jul 13, 2026

04:24
A Mouse Distraction Osteogenesis Model
Published on: November 14, 2018
6.4K
ロビンシーケンスにおける関節分散による合併症の累積的負担
Asli Pekcan1,2, Raina K Patel2, Valeria Mejia1,2
1Division of Plastic and Reconstructive Surgery, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
まとめ
併発症は,ロビンシーケンス (RS) の患者における阻害性睡眠無呼吸症 (OSA) の下分散骨形成 (MDO) の後の主要な合併症と再入院を著しく増加させる. これらの高リスク児の管理には 慎重に手術前評価と手術後の監視が不可欠です
科学分野:
- 小児外科
- 頭蓋骨外科
- 睡眠薬
背景:
- マンジブラー分散骨形成 (MDO) は,ロビンシーケンス (RS) の患者における阻害性睡眠無呼吸症 (OSA) の主要な治療法である.
- RS患者におけるMDOアウトカムに対する併存疾患 (共病) の影響は十分に理解されていません.
- この研究では,RSにおけるMDO後の術後の合併症に対する併発性の負担の影響を調査しています.
研究 の 目的:
- ロビンシーケンス患者のMDO後の併発症と術後の合併症の関連性を評価する.
- 重大な合併症,再入院,再手術を予測する特定の併発症を特定する.
- MDOの結果に対する複数の併発性の累積効果を決定する.
主な方法:
- 2004年から2023年の間に小児病院でMDOを受けたロビンシーケンス患者86人を対象とした遡及コホート研究.
- 収集されたデータには,患者の人口統計,併発性疾患 (呼吸器,心臓,低血圧,胃腸),手術前の挿管状態,および追跡期間が含まれています.
- 評価された主なアウトカムは,多変数ロジスティック回帰を用いて分析された主要な合併症,再入院,再手術でした.
主要な成果:
- 27. 9% の患者が重篤な合併症を経験し,12. 8% が再入院し,19 8% が再手術を受けた.
- 呼吸器系および心臓の併発症は,主要な合併症の独立した予測因子であった (P < .05).
- 合併症の確率は2. 7倍 (P=0. 012),再入院率は4. 2倍 (P=0. 008) 増加した.
結論:
- 併発症の負担は,RS患者の重症合併症,再入院,再手術のリスクに大きく影響する.
- 手術前の挿管は再入院の予測であり, 呼吸器の注意深い管理の必要性を強調しています.
- 手術前スクリーニングの強化,リスクの階層化,患者カウンセリング,手術後の緊密なフォローアップは,MDOを受ける高リスクの患者にとって不可欠です.
関連する概念動画
Mismatch Repair
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Rational Dosage Regimen: Maintenance Dose and Loading Dose
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

